Despite this, there is little preclinical evidence supporting the impact of PARP inhibitors in combination with different radiation modalities (photons and protons), and utilising 3D HNSCC models that more accurately reflect the structure and the treatment of the original tumour. This evidence concerns the gene PARP1 and neoplasm.